{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:01:54Z","timestamp":1785801714493,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008538","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,11,9]],"date-time":"2011-11-09T00:00:00Z","timestamp":1320796800000}}],"reference-count":29,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008538.pub2","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T18:19:44Z","timestamp":1320171584000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sargramostim (GM-CSF) for induction of remission in Crohn's disease"],"prefix":"10.1002","author":[{"given":"Lee","family":"Roth","sequence":"first","affiliation":[{"name":"McMaster University; Faculty of Health Sciences; Institute for Applied Health Sciences, Room 411 1280 Main Street West Hamilton ON Canada L8S 4K1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London Ontario Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John WD","family":"McDonald","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London Ontario Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Chande","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre - Victoria Hospital; Room E1-423A 800 Commissioners Road East London Ontario Canada N6A 5W9"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,9]]},"reference":[{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD008538.pub2-BIB0001|cit1","first-page":"A103","article-title":"Efficacy and safety of sargramostim in moderate to severe Crohn's disease: results of N.O.V.E.L. 4, a phase III multicenter study","volume":"132","author":"Feagan","year":"2007","journal-title":"Gastroenterology"},{"issue":"21","key":"10.1002\/14651858.CD008538.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMoa041109","article-title":"Sargramostim for active Crohn's disease","volume":"352","author":"Korzenik","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008538.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1136\/gut.2008.165738","article-title":"Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"58","author":"Valentine","year":"2009","journal-title":"Gut"},{"issue":"9344","key":"10.1002\/14651858.CD008538.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(02)11437-1","article-title":"Treatment of active Crohn\u2019s disease with recombinant human granulocyte-macrophage colony-stimulating factor","volume":"360","author":"Dieckgraefe","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD008538.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1023\/A:1005541700805","article-title":"Is Crohn\u2019s disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn\u2019s disease","volume":"45","author":"Korzenik","year":"2000","journal-title":"Digestive Diseases and Sciences"},{"issue":"4","key":"10.1002\/14651858.CD008538.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2036.2005.02287.x","article-title":"An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn\u2019s disease","volume":"21","author":"Korzenik","year":"2005","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD008538.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1053\/j.gastro.2005.09.059","article-title":"Adding fuel to the fire: GM-CSF for active Crohn's disease","volume":"129","author":"Moss","year":"2005","journal-title":"Gastroenterology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008538.pub2-BIB0008|cit8","first-page":"S25","article-title":"How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease","volume":"4","author":"Sandborn","year":"2004","journal-title":"Reviews in Gastroenterological Disorders"},{"issue":"6","key":"10.1002\/14651858.CD008538.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-009-0029-7","article-title":"Sargramostim in patients with Crohn\u2019s disease: results of a phase 1-2 study","volume":"44","author":"Takazoe","year":"2009","journal-title":"Journal of Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD008538.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1365-2036.2008.03681.x","article-title":"Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn\u2019s disease","volume":"27","author":"Tine","year":"2008","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD008538.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJM199901213400317","article-title":"Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease","volume":"340","author":"Vaughan","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008538.pub2-BIB0012|cit12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003574.pub2","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","author":"Akobeng","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008538.pub2-BIB0013|cit13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003459.pub2","article-title":"Methotrexate for induction of remission in refractory Crohn's disease","author":"Alfadhli","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008538.pub2-BIB0014|cit14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006792.pub2","article-title":"Traditional corticosteroids for induction of remission in Crohn's disease","author":"Benchimol","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"16","key":"10.1002\/14651858.CD008538.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/jama.1932.02740680019005","article-title":"Regional ileitis: a pathologic and clinical entity","volume":"99","author":"Crohn","year":"1932","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD008538.pub2-BIB0016|cit16","first-page":"1068","article-title":"Chronic interstitial enteritis","volume":"2","author":"Dalziel","year":"1913","journal-title":"British Medical Journal"},{"issue":"9317","key":"10.1002\/14651858.CD008538.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD008538.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"7414","key":"10.1002\/14651858.CD008538.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008538.pub2-BIB0020|cit20","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch8","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]","author":"Higgins","year":"2008. Available from www.cochrane-handbook.org"},{"issue":"12","key":"10.1002\/14651858.CD008538.pub2-BIB0021|cit21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease","author":"Lim","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008538.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1365-2036.2002.01140.x","article-title":"The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review","volume":"16","author":"Loftus","year":"2002","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD008538.pub2-BIB0023|cit23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006097.pub2","article-title":"Natalizumab for induction of remission in Crohn\u2019s disease","author":"MacDonald","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD008538.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0197-2456(97)00051-2","article-title":"Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis","volume":"18","author":"Pogue","year":"1997","journal-title":"Controlled Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD008538.pub2-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000545.pub2","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","author":"Prefontaine","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008538.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008538.pub2-BIB0027|cit27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000296.pub3","article-title":"Budesonide for induction of remission in Crohn's disease","author":"Seow","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD008538.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National cooperative Crohns disease study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1002\/14651858.CD008538.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease","volume":"337","author":"Targan","year":"1997","journal-title":"New England Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008538.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:21:17Z","timestamp":1628547677000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008538.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,11,9]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008538.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,9]]}}}